Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.
Primary Purpose
Breast Cancer
Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Aloe barbadensis topical application in a moisturizing cream vehicle.
Sponsored by

About this trial
This is an interventional prevention trial for Breast Cancer focused on measuring aloe, radiation dermatitis, radiation therapy
Eligibility Criteria
Inclusion Criteria: adult age women receiving 4500cGy or 5000cGy for non-metastatic breast cancer. tumor bed boost allowed. Exclusion Criteria: patients with uncontrolled diabetes, uncontrolled eating disorder, acquired immunodeficiency syndrome, active lupus or scleroderma, a known allergy to pure aloe gel, a pre-study contact dermatitis to study creams. consenting procedures not completed prior to 10cGy of radiation therapy.
Sites / Locations
- Cross Cancer Institute
Outcomes
Primary Outcome Measures
Skin reaction severity.
Secondary Outcome Measures
Symptom severity.
Full Information
NCT ID
NCT00156806
First Posted
September 7, 2005
Last Updated
January 23, 2017
Sponsor
AHS Cancer Control Alberta
1. Study Identification
Unique Protocol Identification Number
NCT00156806
Brief Title
Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.
Official Title
Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
March 2002 (undefined)
Primary Completion Date
May 2005 (Actual)
Study Completion Date
May 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
AHS Cancer Control Alberta
4. Oversight
5. Study Description
Brief Summary
Breast cancer treatment often involved radiation to the breast. A side-effect of this treatment is skin redness, itching and burning. Some patients have quite severe reactions. Our current treatment for this is to avoid any soaps or other skin irritants and to use a moisturizing cream once all radiation is finished. Aloe vera is believed by many people to be useful for treatment of skin burns but this has never been proven in a randomized study. The aim of this study is to compare aloe vera gel versus plan gel versus the standard treatment to determine if there is any benefit. If there was a benefit of gel treatment over standard it could make radiation treatments more tolerable for cancer patients.
Detailed Description
BackgroundRadiation therapy is an important component of treatment for breast cancer, especially in the setting of breast conservation. Even though cancer patients who are receiving radiation treatments follow established hygiene and skin-care protocols they still experience differing degrees of cutaneous skin reactions and associated symptoms of dryness, itchiness, burning sensations, and pain.1-7 For some patients the side-effects associated with radiation therapy can become so severe serious consideration is given to discontinuing treatments. The treatments currently used for reducing cutaneous reactions and symptoms are very limited and often ineffective.5-7 Anti-inflammatories and steroid-based topical pharmaceutical agents are used sparingly due in part to research findings8 and potential harmful side-effects.7 This has left physicians and patients using a trial and error approach in seeking an alternative treatment that will help these patients cope with (and sometimes endure) the cutaneous radiation side-effects. Ongoing clinical experience and discussions with present and former radiation patients reveals that skin irritation, breakdown, pain and associated suffering are common side-effects that patients wish they did not have to experience. The lack of effective, efficient, non-pharmacological treatments for reducing symptoms associated with cutaneous skin reactions to radiation cancer therapy is problematic. Study Objectives the overall aim of the study is to determine if biologically active A. barbadensis is a therapeutic agent for reduction of cutaneous side effects women experience as a result of undergoing radiation therapy for breast cancer.The primary aim is to determine if there is a significant reduction or increase of cutaneous skin reactions using A. barbadensis on the irradiated skin of the breast or chest wall in comparison to following the standard CCI non-pharmacological treatment protocol and in comparison to using the moist inert vehicle gel on the irradiated site.The secondary aim is to explore if there is a reduction or increase in subjective symptoms at the irradiated site with the use of A. barbadensis in comparison to following the standard CCI 'best care' non-pharmacological treatment protocol and in comparison to using the moist inert vehicle gel on the irradiated site.MethodThis study is a single blind randomized controlled trial using a three Arm design. Analysis stratification is being conducted according to radiation technique, breast size, smoker vs. non-smoker, nutrition, protocol adherence, and prior chemotherapy. The control arm will treat the skin reaction as per standard CCI breast radiation protocol
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
aloe, radiation dermatitis, radiation therapy
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
231 (false)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Aloe barbadensis topical application in a moisturizing cream vehicle.
Primary Outcome Measure Information:
Title
Skin reaction severity.
Secondary Outcome Measure Information:
Title
Symptom severity.
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
adult age women receiving 4500cGy or 5000cGy for non-metastatic breast cancer.
tumor bed boost allowed.
Exclusion Criteria:
patients with uncontrolled diabetes, uncontrolled eating disorder, acquired immunodeficiency syndrome, active lupus or scleroderma, a known allergy to pure aloe gel, a pre-study contact dermatitis to study creams.
consenting procedures not completed prior to 10cGy of radiation therapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Donna L. Hoopfer, PhD
Organizational Affiliation
AHS Cancer Control Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cross Cancer Institute
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.
We'll reach out to this number within 24 hrs